CY1117000T1 - Ενζυματικη αντικαρκινικη θεραπεια - Google Patents
Ενζυματικη αντικαρκινικη θεραπειαInfo
- Publication number
- CY1117000T1 CY1117000T1 CY20141100797T CY141100797T CY1117000T1 CY 1117000 T1 CY1117000 T1 CY 1117000T1 CY 20141100797 T CY20141100797 T CY 20141100797T CY 141100797 T CY141100797 T CY 141100797T CY 1117000 T1 CY1117000 T1 CY 1117000T1
- Authority
- CY
- Cyprus
- Prior art keywords
- enzymal
- cancer treatment
- patient
- conjugated
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
Abstract
Παρέχεται μέθοδος θεραπευτικής αγωγής ασθενούς με όγκο, που περιλαμβάνει τη χορήγηση αποτελεσματικής ποσότητας απαμινάσης της αδενοσίνης, κατά προτίμηση συζευγμένης με πολυαλκυλενοξείδιο, σε ασθενή που το έχει ανάγκη.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91303907P | 2007-04-20 | 2007-04-20 | |
EP08754910.1A EP2147122B1 (en) | 2007-04-20 | 2008-04-18 | Enzymatic anticancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117000T1 true CY1117000T1 (el) | 2017-04-05 |
Family
ID=39875909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100797T CY1117000T1 (el) | 2007-04-20 | 2014-10-03 | Ενζυματικη αντικαρκινικη θεραπεια |
Country Status (19)
Country | Link |
---|---|
US (1) | US8741283B2 (el) |
EP (1) | EP2147122B1 (el) |
JP (1) | JP5595904B2 (el) |
KR (1) | KR101540296B1 (el) |
CN (1) | CN101680039B (el) |
BR (1) | BRPI0810384B8 (el) |
CA (1) | CA2684749C (el) |
CY (1) | CY1117000T1 (el) |
DK (1) | DK2147122T3 (el) |
ES (1) | ES2507508T3 (el) |
HR (1) | HRP20140947T1 (el) |
IL (1) | IL201593A (el) |
MX (1) | MX2009011320A (el) |
NZ (1) | NZ580980A (el) |
PL (1) | PL2147122T3 (el) |
PT (1) | PT2147122E (el) |
SI (1) | SI2147122T1 (el) |
TW (1) | TWI486169B (el) |
WO (1) | WO2008131163A1 (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2850323A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
ES2569940T3 (es) | 2007-04-20 | 2016-05-13 | Sigma-Tau Rare Disease Ltd | Adenosina desaminasa recombinante estable |
SG10201600836PA (en) * | 2011-02-03 | 2016-03-30 | Mirna Therapeutics Inc | Synthetic mimics of mir-34 |
CA2964317C (en) | 2014-10-14 | 2021-10-05 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
US10874724B2 (en) * | 2015-05-22 | 2020-12-29 | University Of Houston System | Enzymatic immunomodulation of solid tumors and uses thereof |
EP3426299A4 (en) * | 2016-03-11 | 2019-10-16 | University of Louisville Research Foundation, Inc. | METHOD AND COMPOSITIONS FOR TREATMENT OF TUMORS |
CN110996975A (zh) | 2017-04-13 | 2020-04-10 | 森迪生物科学公司 | 组合癌症免疫疗法 |
TW202035685A (zh) | 2018-10-17 | 2020-10-01 | 美商聖堤生物科技股份有限公司 | 組合癌症免疫療法 |
US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
WO2023086931A2 (en) * | 2021-11-12 | 2023-05-19 | Georgia Tech Research Corporation | Adenosine deaminase 1 compositions and methods for using same |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5346823A (en) * | 1984-05-29 | 1994-09-13 | Genencor, Inc. | Subtilisin modifications to enhance oxidative stability |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5349001A (en) * | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5605976A (en) * | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US5756593A (en) * | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
WO1999030727A1 (en) * | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6624142B2 (en) * | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6251382B1 (en) * | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
US6824766B2 (en) * | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
US6333396B1 (en) * | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
US20020088017A1 (en) * | 1999-04-28 | 2002-07-04 | Board Of Regents, The University Of Texas System | Adenosine deaminase deficient transgenic mice and methods for the use thereof |
US6579857B1 (en) * | 1999-06-11 | 2003-06-17 | Evanston Northwestern Healthcare Research Institute | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors |
WO2001026625A2 (en) * | 1999-10-08 | 2001-04-19 | Alza Corp | Neutral-cationic lipid for nucleic acid and drug delivery |
US20030009017A1 (en) * | 2000-11-08 | 2003-01-09 | Leiby Kevin R. | 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof |
US20040105839A1 (en) | 2001-11-28 | 2004-06-03 | Myung-Ok Park | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
CA2470104C (en) | 2001-12-12 | 2015-01-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
US7413738B2 (en) * | 2002-08-13 | 2008-08-19 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on biodegradable linkers |
US7087229B2 (en) * | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US7122189B2 (en) * | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US20040175804A1 (en) * | 2003-03-04 | 2004-09-09 | Skonezny Paul M. | Process for preparing dideoxyinosine using adenosine deaminase enzyme |
US7301003B2 (en) * | 2005-08-26 | 2007-11-27 | Enzon Pharmaceuticals, Inc. | Method of preparing polymers having terminal amine groups |
US7601798B2 (en) * | 2005-10-04 | 2009-10-13 | Enzon Pharmaceuticals, Inc. | Methods of preparing polymers having terminal amine groups using protected amine salts |
US7989554B2 (en) * | 2006-01-10 | 2011-08-02 | Enzon Pharmaceuticals, Inc. | Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid |
CA2653061A1 (en) | 2006-06-21 | 2007-12-27 | Enzon Pharmaceuticals, Inc. | Stabilized proteins |
CN101534861B (zh) | 2006-09-15 | 2013-10-02 | 安佐制药股份有限公司 | 具有基于位阻酯的生物可降解连接基的聚环氧烷 |
CA2671209A1 (en) * | 2006-12-29 | 2008-07-10 | Enzon Pharmaceuticals, Inc. | Use of adenosine deaminase for treating pulmonary disease |
ES2569940T3 (es) | 2007-04-20 | 2016-05-13 | Sigma-Tau Rare Disease Ltd | Adenosina desaminasa recombinante estable |
-
2008
- 2008-04-18 US US12/105,682 patent/US8741283B2/en active Active
- 2008-04-18 EP EP08754910.1A patent/EP2147122B1/en active Active
- 2008-04-18 DK DK08754910.1T patent/DK2147122T3/da active
- 2008-04-18 WO PCT/US2008/060733 patent/WO2008131163A1/en active Application Filing
- 2008-04-18 CN CN200880021105.8A patent/CN101680039B/zh active Active
- 2008-04-18 JP JP2010504262A patent/JP5595904B2/ja active Active
- 2008-04-18 NZ NZ580980A patent/NZ580980A/en unknown
- 2008-04-18 MX MX2009011320A patent/MX2009011320A/es active IP Right Grant
- 2008-04-18 ES ES08754910.1T patent/ES2507508T3/es active Active
- 2008-04-18 KR KR1020097023239A patent/KR101540296B1/ko active IP Right Grant
- 2008-04-18 PT PT87549101T patent/PT2147122E/pt unknown
- 2008-04-18 SI SI200831301T patent/SI2147122T1/sl unknown
- 2008-04-18 BR BRPI0810384A patent/BRPI0810384B8/pt active IP Right Grant
- 2008-04-18 PL PL08754910T patent/PL2147122T3/pl unknown
- 2008-04-18 TW TW097114405A patent/TWI486169B/zh active
- 2008-04-18 CA CA2684749A patent/CA2684749C/en not_active Expired - Fee Related
-
2009
- 2009-10-18 IL IL201593A patent/IL201593A/en active IP Right Grant
-
2014
- 2014-10-01 HR HRP20140947AT patent/HRP20140947T1/hr unknown
- 2014-10-03 CY CY20141100797T patent/CY1117000T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PL2147122T3 (pl) | 2015-05-29 |
US20090047270A1 (en) | 2009-02-19 |
PT2147122E (pt) | 2014-10-15 |
EP2147122A1 (en) | 2010-01-27 |
IL201593A (en) | 2017-07-31 |
JP5595904B2 (ja) | 2014-09-24 |
WO2008131163A1 (en) | 2008-10-30 |
TWI486169B (zh) | 2015-06-01 |
TW200902051A (en) | 2009-01-16 |
KR20090130108A (ko) | 2009-12-17 |
WO2008131163A8 (en) | 2010-01-28 |
EP2147122B1 (en) | 2014-07-16 |
BRPI0810384B8 (pt) | 2021-05-25 |
US8741283B2 (en) | 2014-06-03 |
CN101680039A (zh) | 2010-03-24 |
HRP20140947T1 (hr) | 2015-02-13 |
EP2147122A4 (en) | 2010-11-17 |
IL201593A0 (en) | 2010-05-31 |
CA2684749C (en) | 2016-06-21 |
JP2010524968A (ja) | 2010-07-22 |
BRPI0810384A2 (pt) | 2014-11-04 |
AU2008242791A1 (en) | 2008-10-30 |
SI2147122T1 (sl) | 2015-01-30 |
CA2684749A1 (en) | 2008-10-30 |
KR101540296B1 (ko) | 2015-07-31 |
CN101680039B (zh) | 2016-08-24 |
MX2009011320A (es) | 2009-12-15 |
DK2147122T3 (da) | 2014-10-13 |
NZ580980A (en) | 2012-04-27 |
RU2009142817A (ru) | 2011-05-27 |
BRPI0810384B1 (pt) | 2021-02-02 |
ES2507508T3 (es) | 2014-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117000T1 (el) | Ενζυματικη αντικαρκινικη θεραπεια | |
CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
CY1124103T1 (el) | Δοσολογικο σχημα που σχετιζεται με ενεσιμους εστερες παλιπεριδονης μακρας δρασης | |
CY1120670T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) | |
CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
CY1119123T1 (el) | Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους | |
CY1117445T1 (el) | Παραγωγα φωσφοραμιδικου της 5-φθορο-2´-δεοξυουριδινης για χρηση στην θεραπεια καρκινου | |
EA202090338A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
EA201290138A1 (ru) | Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция | |
EA201490993A1 (ru) | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи | |
CY1113136T1 (el) | Αντιμετωπιση των διαταραχων των χονδρων με ton fgf-18 | |
CY1123093T1 (el) | Φαρμακοφορο για την επαγωγη του trail | |
EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
EA201290139A1 (ru) | Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких | |
EA201491221A1 (ru) | Новые молекулы, ингибирующие jnk, для лечения различных болезней | |
CY1121244T1 (el) | Συνδυασμος αναστολεα τελομερασης και γεμσιταβινής για τη θεραπεια του καρκινου | |
EA201201474A1 (ru) | Способы лечения рака молочной железы | |
CY1117831T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
CY1116216T1 (el) | Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου | |
CY1121973T1 (el) | Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα | |
GT201300047A (es) | Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante | |
CY1121667T1 (el) | Παραγοντες για θεραπεια τριπλα αρνητικου καρκινου μαστου |